[受限的平均响应持续时间:在瘤学临床试验中评估疗效的新终点]
概括
这项研究引入了受限平均响应持续时间 (RMDOR),这是瘤学试验的新复合终点. 通过整合多种措施,RMDOR克服了传统终点的局限性,提高了治疗效益评估.
科学领域:
- 在瘤学瘤学.
- 临床试验 临床试验
- 生物统计学 生物统计学
背景情况:
- 在瘤学试验中,反应持续时间 (DOR) 由选择偏差所限制,影响随机化.
- 现有的终点在瘤学研究中可能无法完全捕捉治疗疗效.
研究的目的:
- 引入受限平均响应持续时间 (RMDOR) 作为一种新的复合疗效终点.
- 解决瘤学临床试验中单个终点的局限性.
- 提供一种方法,在评估治疗效益的同时保持随机化原则.
主要方法:
- 对RMDOR定义,参数估计和假设测试的系统描述.
- 使用第三期非小细胞肺癌试验数据应用RMDOR.
- 使用"PBIR"套件进行示例分析.
主要成果:
- 在治疗意图层面,RMDOR集成了目标响应率,响应时间和DOR.
- 实例分析表明,RMDOR提供了治疗差异的稳定和合理量化.
- RMDOR有效地弥补了单一疗效终点的局限性.
结论:
- RMDOR是瘤学试验的一个有价值的方法工具.
- 这种新的终点保留了随机化,并全面反映了治疗的好处.
- 建议在未来的研究中将RMDOR与传统终点结合使用.
更多相关视频
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
11.1K
05:39Author Spotlight: Radiotherapy and Clonogenic Assays for Advancing Cancer Research and Personalized Medicine
Published on: April 5, 2024
1.3K
相关概念视频
Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship
68
For drugs producing a quantal response, onset occurs when plasma concentration reaches a minimum effective level (Cmin). The drug's action duration depends on how long the plasma concentration remains above Cmin.Two primary factors influence this duration: dose size and the rate of drug removal from the action site. Both depend on the drug's redistribution to poorly perfused tissues and elimination processes. A larger dose promotes rapid onset and prolongs the effect's duration.Consider a...
68
Kaplan-Meier Approach
663
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
663
Dose Response Curve: Conventional Versus Nonmonotonic
131
The correlation between a drug's dosage and its impact on a biological system is a cornerstone of pharmacology and toxicology. Conventional dose–response curves, which include graded and quantal relationships, are key to this understanding. Graded dose–response curves depict the spectrum of a biological reaction to different doses within an individual, indicating that as the drug dosage increases, so does the intensity of the response. On the other hand, quantal dose–response...
131
Clinical Trials: Overview
5.2K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.2K
Measurement of Bioavailability: Pharmacodynamic Methods
929
Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.
929
Dose-Response Relationship: Overview
5.4K
Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
5.4K
